Allos Therapeutics to Report First Quarter 2011 Results on May 10, 2011

WESTMINSTER, Colo.--(BUSINESS WIRE)-- Allos Therapeutics, Inc. (NASDAQ: ALTH), a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics, today announced that the Company will report its financial results for the first quarter ended March 31, 2011 on Tuesday, May 10, 2011, after the financial markets close. Following the release of the financial results, Allos management will provide a corporate update and review of the first quarter 2011 results via conference call and audio webcast. Access to the conference call and webcast may be obtained as follows:

Time: 4:30 PM ET / 2:30 PM MT

Date: Tuesday, May 10, 2011

Dial-in: 1-877-941-1466 (U.S.) or +480-629-9724 (Canada and international)

Webcast: www.allos.com (homepage and “Investors - Presentations and Events” section)

A recorded rebroadcast will be available for interested parties unable to attend the live conference call by dialing 1-800-406-7325 (domestic) or +1-303-590-3030 (international) and using passcode 4438057#. Webcast and telephone replays of the conference call will be available approximately two hours after the completion of the call through May 24, 2011.

About Allos Therapeutics

Allos Therapeutics, Inc. (Nasdaq: ALTH) is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. Allos is currently focused on the development and commercialization of FOLOTYN® (pralatrexate injection), a folate analogue metabolic inhibitor. FOLOTYN is the first and only drug approved in the U.S. for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma. Allos is also developing FOLOTYN in other hematologic malignancies and solid tumors. Allos retains exclusive worldwide rights to FOLOTYN for all indications. Allos is headquartered in Westminster, CO. For additional information, please visit www.allos.com.

Safe Harbor Statement

The anticipated presentation will contain forward-looking statements that involve significant risks and uncertainties. Additional information concerning these forward-looking statements and other factors that may cause actual results to differ materially from those anticipated in the forward-looking statements is contained in the "Risk Factors" section of the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2011 and in the Company's other periodic reports and filings with the Securities and Exchange Commission. The Company cautions investors not to place undue reliance on the forward-looking statements contained in the presentation. All forward-looking statements are based on information currently available to the Company on the date thereof, and the Company undertakes no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date of these presentations, except as required by law.



CONTACT:

Allos Therapeutics, Inc.
Monique Greer, 720-540-5268
[email protected]

KEYWORDS:   United States  North America  Colorado

INDUSTRY KEYWORDS:   Health  Biotechnology  Oncology  Pharmaceutical  General Health

MEDIA:

Logo
 Logo

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.